Table 2. Univariate analysis of clinical factors for 5-year overall survival (OS) and lung metastasis-free survival (LMFS) in the training set.

Variable	Overall survival			LMFS
	Patient	5-year OS	P-value	Patient	5-year LMFS	P-value
Gender
Male	212	59.8	0.09	181	59.1	0.25
Female	128	69.7		122	62.4
Age
<14 years	103	58.0	0.72	91	56.8	0.25
≥14 years	237	56.0		212	62.0
Histological type
Osteoblastic	272	64.2	0.87	242	60.2	0.56
Chondroblastic	46	60.2		43	59.1
Fibroblastic	10	70.1		8	56.0
Others	12	55.3		10	60.4
Enneking stage
IIA	38	76.5	<0.01	38	79.4	0.05
IIB	265	59.5		265	58.2
III	37	20.3		0
Tumor size
≤8 cm	156	80.9	<0.01	136	82.4	<0.01
>8 cm	184	41.4		167	43.5
Surgery type
Amputation	75	55.8	0.53	60	49.3	0.56
Limb sparing	265	61.6		243	54.7
WBC × 109
<10	271	58.6	0.37	240	64.8	0.03
≥10	69	49.3		63	43.3
Neutrophil × 109
<6.4	263	60.3	<0.01	234	65.1	0.004
≥6.4	77	42.0		69	43.5
Lymphocyte × 109
<3.3	313	55.7	0.14	276	61.4	0.63
≥3.3	27	69.3		27	51.7
Platelet × 109
<300	198	70.6	<0.01	182	76.4	<0.01
≥300	142	41.2		121	39.4
Hemoglobin × 109
<130/120	206	51.0	0.40	189	60.2	0.92
≥130/120	134	62.2		114	60.1
Albumin
<35	8	75.0	0.14	7	85.7	0.41
35–50	311	55.1		277	59.8
≥50	21	67.0		19	65.6
Fibrinogen
<4	268	58.4	0.15	240	65.6	0.03
≥4	72	51.1		63	43.3
LDH
<240	199	61.6	0.01	188	63.8	0.01
≥240	141	50.0		115	54.6
ALP
<110/150	103	88.8	<0.01	97	70.2	0.01
≥110/150	237	46.6		206	56.3

WBC: white blood cell; LDH: lactate dehydrogenase; ALP: alkaline phosphatase; OS: overall survival; LMFS: lung metastasis-free survival.